Brand names: INLYTA
Axitinib is indicated for:
Renal cell carcinoma (RCC)
Irrespective of gender only Adults (18 years old or older)
Axitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 10-20 mg in 2 divided doses daily
Active ingredient Axitinib is contraindicated in the following cases: